Page 10 - Pharma Analyst News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Current therapies for new SARS-CoV-2 variants require adjustments: GlobalData Current therapies for new SARS-CoV-2 variants require adjustments: GlobalData 23 April 2021 | News Source credit: Shutterstock The emergence of new SARS-CoV-2 variants have been detected in over 40 countries and are disrupting drug development worldwide. The prevalence of these more transmissible strains is growing fast and may require adjustments to current therapies to ensure they retain clinical efficacy, says GlobalData. Nancy Jaser, Pharma Analyst, GlobalData, comments, “More data is now required for all pot...

Sputnik V to face stiff competition in India: GlobalData Sputnik V to face stiff competition in India: GlobalData 20 April 2021 | News Source credit: Shutterstock With the Sputnik V vaccine’s recent approval, India now has three vaccines authorised for COVID-19 treatment. However, despite better efficacy over Serum Institute of India/ AstraZeneca’s Covishield and Bharat Biotech’s COVAXIN, Sputnik V will face stiff competition in India, says GlobalData. Dr Reddy's Laboratories (DRL) will receive Sputnik V from the Russian Direct Investment Fund (RDIF) by mid-May 2021 and local produ...

CAR-T therapy leads Singapore medical tourism within APAC 12 April 2021 | Analysis With the approval of Novartis’ Kymriah, Singapore is becoming a popular medical tourism destination within APAC: says GlobalData Photo Credit: GlobalData The inherent heterogeneity of diseases such as cancer is driving the field of personalized (precision) therapies. Within personalized therapies, chimeric antigen receptor (CAR-T) therapies are gaining traction. With the approval of Novartis’ Kymriah, Singapore is now all set to deliver the transformative treatment for cancers and takes the lea...

An interim analysis reveals the Covaxin® (BBV152) vaccine was relatively safe and 81 percent effective in preventing symptomatic COVID-19.

This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website. Manage your cookiesI agree Cookie Settings Cookie Settings This website uses cookies to improve your experience whil...